TERONEVA
Description
Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Drug type
Abiraterone acetate is a type of hormone therapy. This medication is classified as an "adrenal inhibitor"
Indications:
- Metastatic Castration Resistant Prostate Cancer
| Generic Name | Strength | Standard | Type | Packing | Pack Size |
| Abiraterone | 250 mg | USP/IP/IH | Tab | Bottle | 1×60's |